Company Overview of Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical tr...
88 Sidney Street
Cambridge, MA 02139
Founded in 2007
Key Executives for Agios Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $517.5K
Chief Medical Officer
Total Annual Compensation: $553.8K
Chief Scientific Officer
Total Annual Compensation: $400.9K
Compensation as of Fiscal Year 2015.
Agios Pharmaceuticals, Inc. Key Developments
Celgene Corp and Agios Pharmaceuticals, Inc to Develop and Commercialize Companion Diagnostic Tests on Abbott's m2000 Realtime System
Oct 12 16
Celgene Corp. (CELG) and Agios Pharmaceuticals, Inc. (AGIO) announced each company has entered into collaboration agreements with Abbott (ABT) to develop and commercialize companion diagnostic tests on Abbott's m2000 RealTime System to identify isocitrate dehydrogenase, or IDH, mutations in acute myeloid leukemia, or AML, patients. Celgene is currently developing enasidenib, an IDH2 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH2 mutation. Agios is developing AG-120, an IDH1 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation.
Agios Pharmaceuticals, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 02:05 PM
Sep 6 16
Agios Pharmaceuticals, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 02:05 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.
Agios Pharmaceuticals, Inc. Announces Management Changes
Aug 26 16
On August 26, 2016, Marc Tessier-Lavigne, Ph.D. notified Agios Pharmaceuticals, Inc. of his decision to resign as a member of the Board of Directors of the Company, as chairman of the Board and as chairman of the Board’s Science and Technology Committee, effective immediately. Upon his resignation, Dr. Tessier-Lavigne will join the Company’s scientific advisory board. In connection with Dr. Tessier-Lavigne’s resignation, the Board appointed John Maraganore, a member of the Board, to replace Dr. Tessier-Lavigne as chairman of the Board, effective immediately. Additionally, the Board has appointed Lew Cantley, a member of the Board, as chair of the Board’s Science and Technology Committee, effective immediately.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|